CG Oncology (CGON)

Executive Summary

CG Oncology is a late-stage biopharmaceutical company pioneering oncolytic immunotherapy for bladder cancer, with a lead candidate cretostimogene grenadenorepvec (CG0070) targeting non-muscle invasive bladder cancer (NMIBC). The company has received FDA Fast Track and Breakthrough Therapy designations, underscoring the potential of its differentiated approach. CG Oncology maintains a laser-focused pipeline on bladder-sparing therapies, aiming to address high unmet need in BCG-unresponsive NMIBC patients. With a robust Phase 3 program (BOND-003 and CORE-1 trials) and a Phase 2 safety run-in, the company is well-positioned for near-term value inflection. Publicly traded under CGON, the company has a market valuation of approximately $5.3 billion, reflecting high expectations for its lead asset. Clinically, cretostimogene has demonstrated promising efficacy and safety in earlier trials, including a 75% complete response rate at 12 months in high-risk NMIBC. Pivotal Phase 3 data from BOND-003 (NCT04452591) is anticipated in the second half of 2026, which if positive, could support a Biologics License Application (BLA) submission in 2027. The NMIBC market represents a $2+ billion opportunity, and CG Oncology's novel oncolytic mechanism offers a potential paradigm shift from standard intravesical therapies. Key upcoming catalysts include topline data, regulatory clarity on accelerated approval, and potential strategic partnerships to maximize commercial reach.

Upcoming Catalysts (preview)

• Q4 2026Topline data from Phase 3 BOND-003 trial of cretostimogene in BCG-unresponsive NMIBC75% success
• Q2 2026FDA update on accelerated approval pathway or expansion of Breakthrough Therapy designation65% success
• Q3 2026Initiation of Phase 3 CORE-1 trial evaluating cretostimogene in combination with a checkpoint inhibitor (nivolumab) for high-risk NMIBC90% success